NRX Pharmaceuticals Inc - Asset Resilience Ratio
NRX Pharmaceuticals Inc (NRXP) has an Asset Resilience Ratio of 99.01% as of March 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is NRX Pharmaceuticals Inc's working capital to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2019)
This chart shows how NRX Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see total assets of NRX Pharmaceuticals Inc.
Liquid Assets Composition Over Time
This chart breaks down NRX Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read debt load of NRX Pharmaceuticals Inc for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $5.97 Million | 99.01% |
| Total Liquid Assets | $5.97 Million | 99.01% |
Asset Resilience Insights
- Very High Liquidity: NRX Pharmaceuticals Inc maintains exceptional liquid asset reserves at 99.01% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
NRX Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare NRX Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for NRX Pharmaceuticals Inc (2017–2019)
The table below shows the annual Asset Resilience Ratio data for NRX Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2019-12-31 | 99.78% | $32.01 Million | $32.07 Million | -0.17pp |
| 2018-12-31 | 99.96% | $70.77 Million | $70.80 Million | +0.73pp |
| 2017-12-31 | 99.23% | $69.03 Million | $69.57 Million | -- |
About NRX Pharmaceuticals Inc
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in p… Read more